期刊文献+

痛风颗粒抗痛风有效部位群研究 被引量:5

Antigout active fractions in Tongfeng Granule
原文传递
导出
摘要 目的研究痛风颗粒不同提取部位(群)的抗炎、降尿酸作用及对肾脏的影响,筛选痛风颗粒抗痛风的有效部位(群)。方法大鼠足跖注射微晶型尿酸钠制备踝关节肿胀、足跖肿胀模型,腺嘌呤+盐酸乙胺丁醇制备大鼠高尿酸血症模型。通过检测大鼠足肿胀率、血尿酸(UA)值、肌酐(Cr)、血尿素氮(BUN)水平和肾脏系数,筛选痛风颗粒不同提取部位中的有效部位(群)。结果痛风颗粒A部位(主要由黄酮、生物碱、有机酸组成)显示出显著的抗炎、降尿酸和一定的肾脏保护作用:显著抑制尿酸钠致大鼠的足跖肿胀及踝关节肿胀(P<0.01);显著降低高尿酸血症大鼠的血UA、Cr及BUN水平(P<0.01);但与模型组比较,各给药组肾脏系数无显著改变。结论在各提取部位中,A部位降尿酸、抗炎作用最强,与痛风颗粒全方作用强度相当。 Objective To observe the therapeutic effect of the various active fractions in Tongfeng Granule on gouty arthritis, gouty hypericemia with renal protection. Methods The swelling models of ankle and voix pedis in rats were induced by microcrystal monosodium urate (MSU) and the hyperuricemia model in rats was induced by adenine and ethambutol. The swelling rate, blood uric acid (UA) level, creatinine (Cr), blood urea nitrogen (BUN) level, and kidney indexes of rats were measured to screen antigout active fractions in Tongfeng Granule. Results Fraction A (mainly consisting of flavonoids, alkaloids, and organic acids) in Tongfeng Granule showed the significant effect on gouty arthritis, gouty hyperuricemia with certain renal protection; It could significantly reduce the foot swelling rate (P 〈 0.01) and the contents of UA, Cr, and BUN in rats (P 〈 0.01); But compared with the model group, there was no significant difference in kidney indexes. Conclusion Of all the fractions, fraction A has the highest inhibitory effects on inflammation and UA.
出处 《中草药》 CAS CSCD 北大核心 2013年第5期590-594,共5页 Chinese Traditional and Herbal Drugs
基金 上海市卫生局科研课题(2010013)
关键词 痛风颗粒 痛风 有效部位群 尿酸 抗炎 Tongfeng Granule gout active fractions uric acid anti-inflammation
  • 相关文献

参考文献18

二级参考文献148

共引文献1959

同被引文献47

  • 1尚雁君,黄才国,蒋三好,朱大元,魏善建,焦炳华.迷迭香酸对黄嘌呤氧化酶的抑制作用[J].第二军医大学学报,2006,27(2):189-191. 被引量:41
  • 2朱伟,陈可冀,徐筱杰.计算机药物虚拟筛选技术在中医药领域中的应用前景[J].中国中西医结合杂志,2007,27(3):263-266. 被引量:26
  • 3邱雅慧.血管内皮细胞的功能以及损伤修复与动脉粥样硬化[J].中国组织工程研究与临床康复,2007,11(10):1927-1929. 被引量:79
  • 4Schlesinger N. New agents for the treatment of gout and hyperuricemia: febuxostat, puricase, and beyond [J]. Curr RheumatolRep, 2010, 12(2): 130-134.
  • 5Burns C M, Wortmann R L. Gout therapeutics: new drugs for an old disease [J]. Lancet, 2011, 377(9760): 165-177.
  • 6广西壮族自治区壮药质量标准[S].2011.
  • 7Zeng Q Y, Chen R, Darmawan J, et al. Rheumatic diseases in China [J]. Arthritis Res Ther, 2008, 10(1): R17.
  • 8Weaver A L. Epidemiology of gout [J]. Cleve Clin JMed, 2008, 75 (5): S9-S12.
  • 9Kutzing M K, Firestein B L. Altered uric acid levels and disease states [J]. J Pharmacol Exp Ther, 2008, 324(1): 1-7.
  • 10Shimada M, Johnson R J, May W S, et al. A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome [J]. Nephrol Dial Transplant, 2009, 24(10): 2960-2964.

引证文献5

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部